血清IL-6浓度与NK／T细胞淋巴瘤患者临床特征及预后的关系

The relationship between serum IL-6 level and clinical features and prognosis in patients with natural killerfr cell lymphoma

目的探讨NK／T细胞淋巴瘤（NKTCL）病例血清白细胞介素6（IL-6）浓度及其与临床特征、预后的关系。方法收集中山大学肿瘤防治中心2005年1月至2011年12月有治疗前血清的初治NKTCL病例59例，采用夹心酶联免疫吸附法检测血清IL-6水平。结果NKTCL病例血清IL-6显著增高，49例未合并嗜血细胞综合征（Non-HLH）患者为2．56（0-22．29）pg／ml；而10例合并HLH患者为102．11（23．44-5871．24）pg／ml。在发热、晚期、高KPI评分、化疗耐药、高C反应蛋白的NK／TCL病例中，血清IL-6浓度增高患者的比例也显著增高。在生存方面，血清IL-6浓度≥3．12pg／ml的NKTCL病例，其5年无疾病生存（PFS）率为（7．3±5．0）％，5年生存（OS）率为（17．0±7．4）％；而血清IL-6浓度〈3．12pg／ml的NKTCL病例，其5年PFS率为（58．6±9．1）％（P=0．000），5年OS为（62．1±9．0）％（P=0．001）。结论血清IL-6水平增高与NKTCL病例高危临床特征和长期生存差相关。

Objective To investigate the level of serum interleukine-6 （IL-6） in patients with natural killer/T-cell lymphoma （NKTCL） and its significance in clinical characteristics and prognosis. Methods From January 2005 to December 2012, 59 patients with NKTCL in Cancer Center of Sun Yat-sen University were included. Serums from all patients were collected before treatment and the concentration of IL-6 was tested by sandwich ELISA. Results The level of serum IL-6 in patients with NKTCL increased significantly. The median level of IL-6 was 2.56 （0-22.29） pg/ml in 49 patients without hemophagocytic lymphohistiocytosis （HLH）, and 102.11 （23.44-5 871.24） pg/ml in l0 patients with HLH. Patients with high serum IL-6 level were associated with high incidence of fever, advanced stage, high KPI score, poor chemotherapy response, high level of serum C-reactive protein. The 5-year progression free survival （PFS） and 5-year overall survival （OS） were （58.6±9.1）% and （62.1±9.0）% respectively in patients with 〈3.12 mg/ml serum IL-6 level, with statistically significant differences compared with （7.3±5.0）% and （17.0±7.4）% in patients with ≥3.12 mg/ml serum IL-6 level （P=-0.000, 0.001）. Conclusion High level of serum IL-6 might be associated with adverse clinical features and poor survival in patients with NKTCL.